Harmony Biosciences Holdings, Inc. 8-K
Research Summary
AI-generated summary
Harmony Biosciences Reports CFO Change; Glenn Reicin Appointed
What Happened
- Harmony Biosciences Holdings, Inc. (HRMY) filed a Form 8-K on April 14, 2026 announcing that Chief Financial Officer Sandip Kapadia stepped down effective April 14, 2026 and that Glenn Reicin was appointed as the Company’s new CFO effective the same date. The company and Kapadia entered a Separation Agreement providing severance and benefits under his prior agreements in exchange for a release of claims.
Key Details
- New CFO Glenn Reicin: age 61, formerly CFO/Senior Advisor at Eccogene and prior CFO roles at Alladapt and Sigilon; holds an MBA from Harvard and a B.A. from Brandeis. No family relationships or reportable related-party transactions.
- Compensation: Reicin’s base salary is $500,000 and his target annual bonus is 50% of base pay (effective April 14, 2026). He is eligible for standard employee benefits.
- Equity and vesting: Harmony will grant Reicin an option award with a grant-date fair value of $3,000,000. Vesting: 25% after one year, then quarterly vesting over the next three years.
- Severance and change-in-control terms: If terminated without cause or for good reason, Reicin is entitled to (i) cash severance equal to one year’s base salary paid over 12 months, (ii) company-paid health coverage for 12 months, (iii) any earned but unpaid prior-year bonus, and (iv) up to 12 months of outplacement. If termination occurs near a change in control (60 days before to 12 months after), he would also receive a pro-rata target bonus and full accelerated vesting of the option. Agreement includes a Section 280G "best pay" provision and customary confidentiality, non-compete, and non-solicit terms.
Why It Matters
- This 8-K documents a leadership change at the finance function and the contractual compensation and severance terms for the new CFO, which are relevant to investors tracking executive stability, potential near-term compensation expense, and equity dilution from option grants. The change-in-control and severance provisions could accelerate cash or equity obligations in certain scenarios; the company also publicly announced the appointment via a press release filed with the 8-K.